|
Mar 7
|
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
|
|
Mar 4
|
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
|
|
Feb 2
|
Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
|
|
Jan 11
|
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
|
|
Jan 9
|
Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...
|
|
Dec 29
|
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Dec 13
|
Analysts Expect Breakeven For Fortress Biotech, Inc. (NASDAQ:FBIO) Before Long
|
|
Dec 11
|
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
|
|
Dec 6
|
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
|
|
Dec 6
|
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
|
|
Dec 6
|
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
|
|
Dec 5
|
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
|
Dec 1
|
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
|
|
Oct 26
|
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Oct 26
|
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
|
|
Aug 8
|
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|